Effect of the Intensity of Continuous Renal Replacement Therapy

This study has been completed.
Sponsor:
Information provided by:
Zhejiang University
ClinicalTrials.gov Identifier:
NCT01251081
First received: November 30, 2010
Last updated: NA
Last verified: January 2004
History: No changes posted
  Purpose

In patients with sepsis and AKI, increasing the intensity of renal replacement therapy from 50 mL/kg/h (HVHF) to 85 mL/kg/h (EHVHF)will increase the survival at 28 days and 90 days.


Condition Intervention
Optimal Intensity of Renal Replacement Therapy on Sepsis Patients
Other: extra high volume hemofiltration
Other: high volume hemofiltration

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Sepsis and Acute Kidney Injury: Single-center Randomized Clinical Trial

Resource links provided by NLM:


Further study details as provided by Zhejiang University:

Primary Outcome Measures:
  • 90 days survival [ Designated as safety issue: No ]
    The primary study outcome was death from any cause within 90 days. Results were analyzed by Kaplan-Meier survival curves


Secondary Outcome Measures:
  • length of stay in the ICU and hospital [ Designated as safety issue: No ]
    Secondary outcomes were length of stay in the ICU and hospital and renal outcome of survivors at 90 days after randomization.


Enrollment: 280
Study Start Date: January 2004
Study Completion Date: June 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: extra high volume hemofiltration
extra high volume hemofiltration (85 mL/kg/h, EHVHF)
Other: extra high volume hemofiltration
extra high volume hemofiltration (85 mL/kg/h, EHVHF)
Sham Comparator: high volume hemofiltration
high volume hemofiltration (50 mL/kg/h, HVHF)
Other: high volume hemofiltration
high volume hemofiltration (50 mL/kg/h, HVHF)

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

met at least one of the following criteria: oliguria (urine output less than 100 mL in a 6 h period and unresponsive to fluid resuscitation), serum potassium concentration more than 6.5 mmol/L, severe acidemia (pH < 7.2), serum creatinine more than 250 µmol/L, or presence of severe organ edema (e.g. pulmonary edema).

Exclusion Criteria:

  • were presence of a malignant tumor, chronic renal insufficiency (serum creatinine >133 µmol/L), or receiving any kind of renal replacement therapy before randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01251081

Locations
China, Zhejiang
Kidney disease center, the first affiliated hospital, medical college of Zhejiang university
Hangzhou, Zhejiang, China, 310003
Sponsors and Collaborators
Zhejiang University
Investigators
Study Director: jianghua chen, MD Kidney disease center, the first affiliated hospital, medical college of Zhejiang university
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01251081     History of Changes
Other Study ID Numbers: VHVHF
Study First Received: November 30, 2010
Last Updated: November 30, 2010
Health Authority: China: Food and Drug Administration

Keywords provided by Zhejiang University:
high volume hemofiltration
sepsis
acute kidney injury
survival

Additional relevant MeSH terms:
Acute Kidney Injury
Sepsis
Infection
Inflammation
Kidney Diseases
Pathologic Processes
Renal Insufficiency
Systemic Inflammatory Response Syndrome
Urologic Diseases

ClinicalTrials.gov processed this record on October 23, 2014